Zobrazeno 1 - 10 of 38 pro vyhledávání: '"Haolan Lu"'
1
Akademický článek
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
Autor: Jian Li, Yanhong Deng, Weijie Zhang, Ai-Ping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, David Liu, Lin Shen
Publikováno v: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Abstract Background Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafoli
Externí odkaz: https://doaj.org/article/ab1ff6ee93f24c1a9771e179ae7716be
Zobrazit plný text záznamu
3
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors
Autor: Ting Xu, Qiong Hua, Haolan Lu, Wael A. Harb, John Gong, Cody J. Peer, Yue He, Siying Xu, David T.L. Liu, Ruiping Dong, Kyriakos P. Papadopoulos, Ni Lu
Publikováno v: Oncologist
Lessons Learned Subcutaneous injection was an effective route of administration for envafolimab with a favorable pharmacokinetic profile in patients with previously treated advanced solid tumors. Subcutaneous envafolimab was well tolerated and had du
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f752d381ffe5d46a68a748dbed37371
https://doi.org/10.1002/onco.13817
Zobrazit plný text záznamu
5
A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)
Autor: Daniel P. Petrylak, Tyler F. Stewart, Xin Gao, Elmer Berghorn, Haolan Lu, Edward Chan, Richard Gedrich, Joshua Michael Lang, Meredith McKean
Publikováno v: Journal of Clinical Oncology. 41:TPS290-TPS290
TPS290 Background: Patients with mCRPC inevitably develop resistance to available therapies and lack curative options. In patients treated with novel hormonal agents (NHAs), mutations can develop in the ligand-binding domain (LBD) of the AR gene, som
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2a536ca63ff031ec39c5de1d5e09b2a
https://doi.org/10.1200/jco.2023.41.6_suppl.tps290
Zobrazit plný text záznamu
6
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
Autor: Yanhong Deng, Weijian Guo, John Gong, Lin Shen, Jianwei Yang, Silong Xiang, Shukui Qin, Ying Yuan, Ai-Ping Zhou, David T.L. Liu, Weijie Zhang, Ting Xu, Liangjun Zhu, Haolan Lu, Jian Li
Publikováno v: Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
BackgroundMonoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a hum
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09bbb0b951625540543c04057137cd3d
https://doi.org/10.1186/s13045-021-01095-1
Zobrazit plný text záznamu
7
Phase 1b study of bavdegalutamide, an androgen receptor PROTACdegrader, combined with abiraterone in patients with metastatic prostate cancer
Autor: Neal D. Shore, John Shen, Michael Edward Devitt, Haolan Lu, Jeanette Alicea, Janaki Parameswaran, Deborah Chirnomas, Xin Gao, Meredith McKean
Publikováno v: Journal of Clinical Oncology. 40:TPS5106-TPS5106
TPS5106 Background: Bavdegalutamide (ARV-110) is a novel, oral PROteolysis TArgeting Chimera (PROTAC) protein degrader that targets wild-type androgen receptor (AR) and clinically relevant mutants. Bavdegalutamide demonstrated tumor growth inhibition
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8a53a1b868c5842d7d278805bdac7df
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5106
Zobrazit plný text záznamu
8
ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study
Autor: Erika P. Hamilton, Anne F. Schott, Rita Nanda, Haolan Lu, Chi Fung Keung, Richard Gedrich, Janaki Parameswaran, Hyo S. Han, Sara A. Hurvitz
Publikováno v: Journal of Clinical Oncology. 40:TPS1120-TPS1120
TPS1120 Background: ARV-471 is a novel, potent, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) protein degrader that selectively targets the ER. In xenograft models, ARV-471 demonstrated substantially greater ER degradation and antitumor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::702bee39736891f26a39c9e3f309a52e
https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120
Zobrazit plný text záznamu
10
Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer
Autor: Yuxi, Zhang, Yi, Wang, Yanping, Li, Cong, Huang, Xiaoqian, Xiao, Zhanqiong, Zhong, Jingyi, Tang, Haolan, Lu, Yibei, Tang, Jiahui, Yang
Publikováno v: Biochemical Pharmacology. 198:114941
Non-small cell lung cancer (NSCLC) cells exhibit aberrant metabolism characterized by high glycolysis even in the presence of abundant oxygen. Inhibition of aerobic glycolysis remains challenging when identifying potential cancer-specific inhibitors
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbac2dfaf39ed79dcefafd61a9c218ad
https://doi.org/10.1016/j.bcp.2022.114941
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje